Goldman-Backed Biotech Attovia Raises $289 Million in US IPO
· Financial Post
(Bloomberg) — Attovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range. Read More
Visit chickenroad-game.rodeo for more information.